Importantly, the biallelic mutations of MRE11 account for roughly 39% of MSI cancers, and across 70 MSI primary human cancers, MRE11 mutations occurred in 83.7 and 50% of colorectal and endometrial cancers, respectively [31]. This evidence concerns the gene MRE11 and endometrial cancer.